<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01913353</url>
  </required_header>
  <id_info>
    <org_study_id>POX-MVA-006</org_study_id>
    <nct_id>NCT01913353</nct_id>
  </id_info>
  <brief_title>A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®</brief_title>
  <official_title>A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Army Medical Research Institute of Infectious Diseases</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Bavarian Nordic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy of MVA-BN® by showing that vaccination prior to administration of
      ACAM2000® results in an attenuated take.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate the efficacy of MVA-BN® by assessing non-inferiority of MVA-BN® compared to
      ACAM2000® in terms of vaccinia-specific Plaque Reduction Neutralization Test (PRNT) antibody
      response at the Peak Visits (Day 42 for Group 1 and Day 28 for Group 2) and by showing that
      vaccination with MVA-BN® prior to administration of ACAM2000® results in an attenuation of
      take.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PRNT GMT at the Peak Visits</measure>
    <time_frame>Day 42 for Group 1 and Day 28 for Group 2</time_frame>
    <description>To demonstrate the efficacy of MVA-BN® by assessing non-inferiority of MVA-BN® compared to ACAM2000® in terms of vaccinia-specific PRNT antibody response at the Peak Visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Lesion Area (MLA) in mm² after scarification with ACAM2000®</measure>
    <time_frame>Day 6-8, 13-15 after 3rd Vaccination for Group 1 and Day 6-8, 13-15 after first vaccination for Group 2</time_frame>
    <description>To demonstrate the efficacy of MVA-BN® by assessing non-inferiority of MVA-BN® compared to ACAM2000® in terms of showing that vaccination with MVA-BN® prior to scarification with ACAM2000® results in an attenuation of take.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>18-42 Year Old Healthy Vaccinia-naïve Subjects</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two vaccinations; MVA BN ®; administered 4 weeks apart (Day 0 and Day 28) followed by a single vaccination of ACAM2000® vaccine 4 weeks after the second MVA BN® vaccination (Day 56).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single vaccination of ACAM2000® will be administered at Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA BN®</intervention_name>
    <description>0.5 ml MVA BN® with a nominal titre of 1x10E8 TCID50, administered as a subcutaneous injection</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>IMVMAUNE</other_name>
    <other_name>IMVANEX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACAM2000®</intervention_name>
    <description>0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female subjects, 18-42 years of age

          2. The subject has read, signed and dated the Informed Consent, having been advised of
             the risks and benefits of the trial in a language understood by the subject and prior
             to performance of any trial specific procedure

          3. Acceptable medical history by screening evaluation and physical examination

          4. BMI greater or eaqual than 18.5 and samller than 35

          5. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at
             Screening and a negative urine or serum pregnancy test within 24 hours prior to each
             vaccination

          6. WOCBP must have used an acceptable method of contraception for 28 days prior to the
             first vaccination, must agree to use an acceptable method of contraception during the
             trial, and must avoid becoming pregnant for at least 28 days after the last
             vaccination. A woman is considered of childbearing potential unless post-menopausal or
             surgically sterilized. (Acceptable contraception methods are restricted to abstinence,
             barrier contraceptives, intrauterine contraceptive devices or licensed hormonal
             products)

          7. Human Immunodeficiency Virus (HIV) antibody negative, hepatitis B surface antigen
             negative and negative antibody test to hepatitis C virus

          8. White blood cells greater or eaqual than 2500/mm3 and smaller than 11,000/mm3

          9. Hemoglobin within normal limits

         10. Platelets greater or eaqual than lower normal limits

         11. Adequate renal function defined as a calculated Creatinine Clearance (CrCl) greater
             than 60 ml/min as estimated by the Cockcroft-Gault equation

         12. Adequate hepatic function in the absence of other evidence of significant liver
             disease defined as:

               -  Total bilirubin greater than 1.5 x Upper Limit Normal (ULN)

               -  Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) greater than 1.5
                  x ULN

               -  Alkaline Phosphatase (Alk Phos) greater than 1.5 x ULN

         13. Troponin I smaller than 2 x ULN

         14. Electrocardiogram (ECG) without clinically significant findings, e.g. any kind of
             atrioventricular or intraventricular conditions or blocks such as complete left or
             right bundle branch block, atrioventricular node block, QTc or PR prolongation,
             premature atrial contractions or other atrial arrhythmia, sustained ventricular
             arrhythmia, two premature ventricular contractions in a row, ST elevation consistent
             with ischemia

        Exclusion Criteria:

          1. Pregnant or breast-feeding women

          2. Typical vaccinia scar

          3. Known or suspected history of smallpox vaccination defined as visible vaccination scar
             or documentation of smallpox vaccination or as reported by the subject

          4. History of vaccination with any poxvirus-based vaccine

          5. History of any serious medical condition, which in the opinion of the investigator
             would compromise the safety of the subject

          6. History of or active immunodeficiency or immunosuppression caused by acquired or
             congenital diseases or caused by ongoing treatments such as chronic (greater than 14
             days) high-dose corticosteroids (smaller than 5 mg prednisone [or equivalent] per day
             applied systemically, i.e. parenterally or orally), chronic or planned treatment with
             steroid eye drops or ointment at time of enrollment or radiation, or immunosuppressive
             drugs; low-dose corticosteroid topical products and nasal sprays used sporadically,
             i.e. pro re nata (according to circumstances) are permissible

          7. Having had radiation or X-ray treatment (not routine X-rays) within the last 3 months

          8. Post organ and bone-marrow transplant subjects whether or not receiving chronic
             immunosuppressive therapy

          9. Eye surgery within 4 weeks prior to trial vaccination

         10. History of or active autoimmune disease. Persons with vitiligo or thyroid disease
             taking thyroid hormone replacement are not excluded

         11. Uncontrolled serious infection, i.e. not responding to antimicrobial therapy

         12. History of malignancy, other than squamous cell or basal cell skin cancer, unless
             there has been surgical excision considered to have achieved cure. Subjects with
             history of skin cancer must not be vaccinated at the previous site of cancer

         13. History of keloid formation

         14. History or clinical manifestation of severe hematological, renal, hepatic, pulmonary,
             central nervous, cardiovascular or gastrointestinal disorders

         15. History of coronary heart disease, myocardial infarction, angina, congestive heart
             failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood
             pressure, or any other heart condition under the care of a doctor

         16. Chest pain (that is diagnosed as cardiac related) or trouble breathing on exertion

         17. Ten percent or greater risk of developing a myocardial infarction or coronary death
             within the next 10 years using the National Cholesterol Education Program's Risk
             Assessment Tool: http://hin.nhlbi.nih.gov/atpiii/calculator.asp NOTE: This criterion
             applies only to subjects 20 years of age and older

         18. History of an immediate family member (father, mother, brother, or sister) who has had
             onset of ischemic heart disease before the age of 50 years

         19. Clinically significant psychological disorder not adequately controlled by medical
             treatment

         20. Active or history of chronic alcohol abuse and/or intravenous and/or nasal drug abuse
             (within the past 6 months)

         21. History of anaphylaxis or any severe allergic reaction or serious adverse reaction to
             a vaccine

         22. Eczema of any degree or history of eczema

         23. People with active atopic dermatitis (AD) [characterized by pruritus, eczematous
             lesions, xerosis (dry skin), and lichenification (thickening of the skin and an
             increase in skin markings] or with a history of AD

         24. People with chronic exfoliative skin disorders/conditions

         25. People with active current Varicella zoster, Herpes zoster, impetigo, uncontrolled
             acne, Darier's disease or any acute skin disorders of large magnitude, e.g.,
             laceration requiring sutures

         26. People with a tattoo that covers the vaccination injection area (preventing assessment
             of the area and interfering with a vaccination site photograph)

         27. Having received any vaccinations or planned vaccinations with a live vaccine within 28
             days prior to or after trial vaccination

         28. Having received any vaccinations or planned vaccinations with a killed vaccine within
             14 days prior to or after trial vaccination

         29. Administration or planned administration of immunoglobulins and/or any blood products
             during a period starting from three months prior to administration of the vaccine and
             ending at trial conclusion

         30. Use of any investigational or non-registered drug or vaccine other than the trial
             vaccines within 28 days preceding the first dose of the trial vaccine or planned
             administration of such a drug /vaccine during the trial period

         31. Blood donation for the duration of the trial

         32. Acute disease (illness with or without a fever) at the time of enrollment

         33. Temperature ≥ 100.4°F (38.0°C) at the time of enrollment

         34. Known household contacts with, or occupational exposure (other than minimal contact)
             to any of the following:

               -  Pregnant women

               -  Children &lt;12 months of age

               -  People with eczema or a history of eczema

               -  People with active AD or history of AD

               -  People with chronic exfoliative skin disorders/conditions

               -  People with active Varicella zoster, Herpes zoster, impetigo, uncontrolled acne,
                  Darier's disease or any acute skin disorders of large magnitude, e.g., laceration
                  requiring sutures, burn with areas greater than 2×2 cm

               -  People with active or recent immunodeficiency disease or use of immunosuppressive
                  medications, for example: have or take medication for HIV, AIDS, leukemia,
                  lymphoma, or chronic liver problem, have or take medication for Crohn's disease,
                  lupus, arthritis, or other immune disease; have had radiation or X-ray treatment
                  (not routine X-rays) within the last 3 months; have ever had a bone-marrow or
                  organ transplant (or take medication for that ); or have another problem that
                  requires steroids, prednisone or a cancer drug for treatment

               -  People having had eye surgery within the last 4 weeks

         35. Known allergy to MVA-BN® vaccine or any of its constituents, e.g.
             tris(hydroxymethyl)-amino methane, including known allergy to egg or aminoglycoside
             (gentamycin)

         36. Known allergies to ACAM2000® and its diluents including polymyxin B sulfate, neomycin
             sulfate, and phenol

         37. Known allergies to vaccinia immunoglobulin (VIG) including thimerosal or previous
             allergic reaction to immunoglobulins

         38. Known allergies to cidofovir, sulfa drugs, or probenecid

         39. Trial personnel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip R Pittman, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>United States Army Medical Research Institute of Infectious Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brian Allgood Army Community Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2013</study_first_submitted>
  <study_first_submitted_qc>July 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2013</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccinia</mesh_term>
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

